SOURCE: Prostalund, Inc.

May 04, 2005 16:26 ET

New CoreTherm Medical Device Treats Enlarged Prostates Faster With Optimum Results

Swedish Company Prostalund Enters U.S. Market With Opening of Los Angeles Office

LOS ANGELES, CA -- (MARKET WIRE) -- May 4, 2005 -- Prostalund® AB, a Swedish developer and manufacturer of medical devices, today announced the opening of Prostalund, Inc., a wholly owned subsidiary based in Los Angeles, California. ProstaLund is the developer of CoreTherm®, a unique medical device that utilizes minimally invasive, microwave thermotherapy to treat an enlarged prostate (BHP - benign prostatic hyperplasia), which affects millions of men in the U.S. CoreTherm, administered on an outpatient basis, provides the fastest treatment for patients, produces results equivalent to surgery, and has lower costs than surgery or drug therapy.

CoreTherm received FDA approval in 2003 and has successfully treated approximately 15,000 patients worldwide. It is now available to hospitals, clinics, and physicians in the U.S. and Canadian markets.

"We believe CoreTherm offers the best treatment option for the millions of men with moderate to severe symptoms of BHP," stated Magnus Bolmsjö, founder and CEO of ProstaLund AB. "Our new Los Angeles office will allow us to fully develop the U.S. market and support physicians and healthcare organizations with a product designed to improve patients' lives and well being."

About the Problem (Benign Prostate Hyperplasia - Enlarged Prostate)

Virtually every other man over the age of 50 will over time be affected by urination problems due to benign prostate hyperplasia, BPH. This condition causes troublesome symptoms and anxiety that adversely affects quality of life for millions of men around the world. Addressing a patient's BPH problem often becomes a choice between surgery, a minimally invasive procedure or symptom-controlling medication.

In the past few years, a new type of minimally invasive methods to treat BPH have become the treatment of choice for more and more patients. These minimally invasive methods involve the use of microwave thermotherapy to reduce the size of the prostate. Prostalund's CoreTherm method utilizes its own innovative technologies to provide temperature feedback and control during the procedure in order to produce better results.

About CoreTherm

CoreTherm's unique features and patented design make it the most advanced minimally invasive procedure available today for the treatment of BHP. No other minimally invasive, microwave thermotherapy devices have these capabilities.

Accurate Monitoring of Intraprostatic Temperature: By accurately monitoring the temperature of the prostate during the procedure, physicians can see the real-time effects of the treatment in progress. Without this monitoring, patients are frequently (up to 40%) under treated, which leads to less than optimal results or even the need to be treated again in the future.

Adjustable Microwave Power/Temperature Control: CoreTherm allows the physician to precisely adjust the temperature to treat each individual patient's condition. This control is important because it reduces the chances the prostate is either over treated or under treated.

Fastest Treatment Time: CoreTherm treats patients in 10-15 minutes, while other microwave thermotherapy devices require 30-60 minutes of treatment. Patients greatly appreciate this benefit.

Best Results: CoreTherm is the only minimally invasive microwave thermotherapy device that consistently reduces patient symptoms from severe to mild. Other minimally invasive procedures only reduce the symptoms from severe to moderate.

About Prostalund

ProstaLund, Inc., based in Los Angeles, is a wholly owned subsidiary of Prostalund AB in Sweden. Prostalund is the developer and manufacturer of the unique and patented CoreTherm medical device for treatment of benign prostatic hyperplasia, based on a unique customized microwave treatment that takes place while monitoring the temperature of the prostate. Prostalund has approximately forty employees in Sweden, a subsidiary in Germany, and sales and distribution organizations throughout Europe, the Middle East, China and the rest of the world. The company's operations are carried out in close collaboration with leading universities and hospitals in Sweden, the U.S., and around the world.

For more information including clinical findings, sales, and distribution, contact Prostalund, Inc. at (310) 559-6015 or visit their Web site at

Contact Information

  • Media Contact
    TopSpin Communications, Inc.
    Joe Waldygo
    Phone: 480-632-5050